Robert F. Kennedy Jr. declined to endorse the CDC’s latest vaccine guidelines, saying he would not commit to the agency’s recommendations. His stance echoes earlier criticism of the department, especially after the dismissal of former director Monarez. Kennedy’s opposition frames the current debate over vaccine data and public trust.

The controversy centers on a study the CDC chose to drop, which found the 2025–2026 COVID‑19 vaccine cut emergency‑department visits by 50 percent and hospitalizations by 55 percent among healthy adults. The data had cleared peer review and was slated for the Morbidity and Mortality Weekly Report on March 19 before being shelved.

Acting CDC director Jay Bhattacharya cited methodological concerns, though the study employed a standard design used in recent flu vaccine research. A spokesperson for HHS, Andrew Nixon, said scientists were addressing the issues, yet the Post reports the manuscript was ultimately rejected after an editorial review. This decision fuels skepticism about the agency’s transparency.

The CDC’s retreat from publishing the study erodes confidence in its data handling and hampers public health messaging. With vaccine hesitancy already high, the agency’s hesitation to share evidence that could reassure the public risks widening the gap between science and policy. Stakeholders now demand clearer criteria for data release.